PTGS2 and skin basal cell carcinoma: A possible important future research pathway could stem from the possible inhibition of BCC development and/or progression by using non-steroidal anti-inflammatory drugs (NSAIDs), namely cyclooxygenase-2 (COX-2) inhibitors, which the current literature data report as having chemoprotective properties in patients with such pathology [57].